Welcome to the Oncology Network for Excellence. Below is a transcript of our recent conversation with Dr. John Eckardt who provides us an overview on the impact of targeted therapies on selective pathways.
Dr. Eckardt is a board certified medical oncologist who has 20 years of experience in patient care, oncology drug development, and oncology education. Dr. Eckardt is now the Chief Medical Officer at DAVA Oncology.
